Speakers - 2026

Abstract

The expression and clinical significance of ETS like-1 protein (ELK1), RAD51 recombinase (RAD51) ,Breast Cancer Susceptibility Gene1(BRCA1, Poly-ADP-ribose polymerase 1 (PARP1）in high-grade serous ovarian cancer were investigated.Methods: Using immunohistochemical techniques, the expression of ELK1, RAD51, BRCA1, and PARP1 proteins was detected in 84 cases of ovarian highgrade serous cancer tissue (experimental group) and 30 cases of non-tumorigenic ovarian tissue (control group).The experimental data were analyzed using the statistical software SPSS 25.0. the difference is statistically significant when P<0.05.Results:(1)Positive protein expression in experimental and control groups,ELK1 protein: 86.9% and 3.3% in the experimental group and control group, respectively, (P < 0.001); RAD51 protein: 84.5% and 0% in the experimental group and control group, respectively, (P < 0.001);BRCA1 protein: 35.7% and 66.7% in the experimental group and control group, P=0.003 (P < 0.05); PARP1 protein: 78.6% and 6.6% in the experimental group and control group, respectively, (P < 0.001); PARP1 protein: the positive expression rate was 78.6 % and 6.6 % in the experimental and control group, respectively, (P < 0.001).(2)Correlation of expression between ELK1, RAD51, BRCA1 and PARP1 proteins,ELK1 protein expression was positively correlated with RAD51 and PARP1 protein expression (P < 0.05), and RAD51 protein expression was positively correlated with PARP1 protein expression (P < 0.05); ELK1, RAD51, and PARP1 protein expression were all negatively correlated with BRCA1 protein expression (P < 0.05).(3)Relationship between positive expression of ELK1, RAD51, BRCA1 and PARP1 proteins and clinicopathologic characteristics of patients, ELK1, RAD51 and PARP1 protein expression were positively correlated with the FIGO stage of the tumor (P < 0.05), and BRCA1 protein expression was negatively correlated with the FIGO stage of the tumor (P < 0.05); there was no statistically significant difference between ELK1, RAD51, BRCA1, and PARP1 protein expression and the age of the patients (P > 0.05).(4)ELK1, RAD51, BRCA1 and PARP1 protein expression and prognosis of high-grade serous ovarian cancer,The results of univariate analysis showed that positive expression of ELK1 and PARP1 proteins and FIGO stage were risk factors affecting the prognosis of high-grade serous ovarian cancer (P < 0.05); positive expression of BRCA1 protein was a protective factor affecting the prognosis of high-grade serous ovarian cancer (P < 0.05); and positive expression of RAD51 was not significantly correlated with the prognosis (P > 0.05). The results of multifactorial analysis showed that the expression level of ELK1 and FIGO stage were independent predictors of prognosis in high-grade serous ovarian cancer (P < 0.05).Conclusions:(1)ELK1, RAD51 and PARP1 proteins were highly expressed in high-grade serous ovarian cancer and positively correlated with FIGO stage. BRCA1 protein was lowly expressed in high-grade serous ovarian cancer  and negatively correlated with FIGO stage, suggesting that these four proteins may be involved in the development of high-grade serous ovarian cancer .(2)In high-grade serous ovarian cancer, there was a positive correlation between ELK1 protein expression and the expression of RAD51 and PARP1 proteins, and a negative correlation with the expression of BRCA1 proteins, suggesting that ELK1 may contribute to the development of serous ovarian cancer through the regulation of homologous recombination-related genes.(3)The expression levels of ELK1 and PARP1 proteins and FIGO stage were risk factors affecting the prognosis of patients, and BRCA1 was a protective factor affecting the prognosis of high-grade serous ovarian cancer. Among them, ELK1 expression level and FIGO stage were independent predictors of the prognosis of high-grade serous ovarian cancer.

Keywords: ELK1, RAD51, BRCA1, PARP1, Homologous Recombination